Latest Conference Articles

While overall data did not suggest a benefit for the drugs, a look at the effects on patients whose cardiac arrests were witnessed shows the benefit of reaching patients quickly.

The data were submitted to the FDA following idarucizumab’s accelerated approval last year, which is granted to therapies that address an unmet medical need.

Results from the GAUSS-3 trial presented Sunday at the American College of Cardiology should be good news for Amgen, but an editorial in JAMA says the cost of evolocumab exceeds "willingness to pay" limits.

A small study of sudden out-of-hospital deaths raises questions about the quality of primary care, especially for women.

The 2013 guideline update from the American College of Cardiology and the American Heart Association drew criticism when it was presented. Data presented in today's poster session at the ACC Scientific Session revealed unexpected results.

The half-day program covered healthy eating, how to prescribe exercise, evidence about stress reduction, and other lifestyle topics, as part of the American College of Cardiology's focus on prevention.

Greetings from First Lady Michelle Obama and a lecture from a non-cardiologist on population health set the stage for the 65th Scientific Session of the American College of Cardiology. Prevention is the focus of this year's meeting.

Results from the HOPE-3 trial, presented on the opening day of the 65th Scientific Session of the American College of Cardiology, suggest cholesterol-lowering statins could have preventive benefits in broader groups of patients than previously thought.

Four panelists and 2 moderators discussed the issues surrounding cancer and healthcare in the lead-up to the 2016 presidential election during the National Comprehensive Cancer Network 21st Annual Conference.

There are a number of lessons oncologists have learned as the population of women who were diagnosed with breast cancer at a younger age grow older, said Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.

While these "generic" biologicals have been deemed to have the potential to create competition and result in healthcare savings-although not to the extent of generic products-technical issues with manufacturing these products have troubled drug manufacturers.

At the National Comprehensive Cancer Network (NCCN) 21st Annual Conference, Alan P. Venook, MD, professor of Clinical Medicine at the University of California, San Francisco, provided insight into lessons learned by oncologists in the treatment of colorectal cancer.

Now that 1 biosimilar has made it to market in the United States, Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine, expects more to follow and that, hopefully, biosimilars will help achieve cost savings for healthcare.

Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network (NCCN), discussed calculating value in cancer care and the dimensions of NCCN's value assessment framework, Evidence Blocks.

At the National Comprehensive Cancer Network (NCCN)'s 21st Annual Conference, Robert Carlson, MD, chief executive officer, NCCN, provided a flavor for their value framework, the Evidence Blocks.

At the National Comprehensive Cancer Network 21st Annual Conference, John A. Thompson, MD, presented an update on where the field of melanoma treatment stands today.

Palliative care should be introduced as early as possible, even as early as diagnosis, so patients hear about it early and not during a late stage of their disease when they might need hospice, Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing, said at the National Comprehensive Cancer Network Annual Meeting.

High-quality cancer care must include palliative care in addition to the more traditional care, such as oncology, radiology, surgery, and imaging, Toby C. Campbell, MD, MSCI, associate professor of medicine, hematology-oncology at the University of Wisconsin School of Medicine and Public Health and chief of Palliative Care and program director of the Hospice and Palliative Medicine Fellowship Training Program, said at the National Comprehensive Cancer Network Annual Conference.

During the opening session at the National Comprehensive Cancer Network 21st Annual Conference, healthcare providers came together to discuss palliation from the provider and the patient perspective.

Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.

Despite the fact that warfarin is more easily reversible, bleeding complications with the therapy are associated with longer stays in the hospital and higher mortality than dabigatran and rivaroxaban.

Research on the post-marketing surveillance of rivaroxaban found that the drug was as safe as determined from the results of the anticoagulant’s randomized controlled trial.

Patients with atrial fibrillation and renal disease who were treated with rivaroxaban (Xarelto) had less of a risk of fatal bleeding, according to a study presented at the American Heart Association Scientific Session.

Physicians are sticking with what they know when it comes to prescribing treatment for deep vein thrombosis and pulmonary embolism. Researchers found that the most common treatment remains parenteral anticoagulant with warfarin despite the arrival of a the new treatment option rivaroxaban.

Using rivaroxaban in a patients with non-valvular atrial fibrillation can reduce rates of stroke and major bleeding, according to the result of the XANTUS study.

Primary clinical reviewers from the FDA and 2 clinician experts provided their unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma: daratumumab (Darzalex), ixazomib (Ninlaro), and elotuzumab (Empliciti).

Results from a subgroup analysis of the phase 3 ENDEAVOR study and a phase 2 study in diffuse large B cell lymphoma patients were presented at the annual meeting of the American Society of Hematology.

Members from the American Society of Hematology (ASH)'s Choosing Wisely Task Force presented 5 recommendations on Monday, December 7, 2015, at the 57th annual meeting of ASH, in Orlando, Florida.